x
CME-Tagline

Safety and Efficacy of Emerging Treatments in the Management of Systemic Lupus Erythematosus (SLE)

CMEO Podcast

Premiere Date: Thursday, February 11, 2021

This activity offers CE credit for:

  1. Physicians (CME)
  2. Pharmacists (ACPE)
  3. ABIM (MOC)
  4. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date: Friday, February 11, 2022

Faculty


Allan Gibofsky, MD, JD, MACR, FACP, FCLM Allan Gibofsky, MD, JD, MACR, FACP, FCLM 
Professor of Medicine
Weill Cornell Medicine
Attending Rheumatologist
Co-Director, Clinic for Inflammatory Arthritis
Hospital for Special Surgery
New York, NY

Richard A. Furie, MD Richard A. Furie, MD 
Professor of Medicine, Zucker School of Medicine at Hofstra/Northwell
Chief, Division of Rheumatology, Northwell Health
Great Neck, NY

Statement of Need

When measuring outcomes in systemic lupus erythematosus (SLE), it is important for clinicians to monitor disease activity, health-related quality of life, and any irreversible change in the organ system that occurred since the onset of SLE. While there are currently many therapies utilized in treating SLE, such as nonsteroidal anti-inflammatory drugs (NSAIDs), steroids, antimalarials, immunosuppressants, chemotherapy, biologics, and adjunctive therapies, there are still unmet needs with a mortality rate at 15 years as well as complications such as lupus nephritis and severe extrarenal disease.

However, the future is bright for patients with lupus, as drug development activities are currently unprecedented. In this CMEOCast podcast episode, expert faculty evaluate the safety and efficacy of these emerging therapies.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Evaluate the safety and efficacy of emerging treatments in the management of SLE.

Financial Support

Supported by an educational grant from AstraZeneca Pharmaceuticals

Target Audience

Rheumatologists, dermatologists, primary care physicians, PAs, nurse practitioners, nurses, and pharmacists

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CPE Credit (Pharmacists):
ACPE CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. .5 contact hours (0.05 CEUs) Universal Activity Number:
Enduring: 0376-0000-21-036-H01-P

Type: Knowledge-based

ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learning Formats
Enduring material

Royal College MOC: Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Note to PAs: PAs may claim a maximum of .5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Gibofsky reports that he is on the advisory committee for AbbVie Inc.; Aurinia Pharmaceuticals Inc.; Eli Lilly and Company; Gilead Sciences, Inc.; Novartis; Pfizer Inc.; and Samumed. He is a consultant for AbbVie Inc.; Acquist Therapeutics, Inc.; Amgen Inc.; Eli Lilly and Company; Gilead Sciences, Inc.; Novartis; Pfizer Inc.; and Samumed. He is a stock shareholder (directly purchased) for AbbVie Inc.; Johnson & Johnson; Pfizer Inc.; and Regeneron Pharmaceuticals, Inc.

Dr. Furie reports that he receives research support from Amgen Inc.; AstraZeneca/Medimmune; Biogen Idec; Boehringer-Ingelheim; Bristol-Myers Squibb Company; Eli Lilly and Company; Genentech, Inc./Roche; GlaxoSmithKline; Kezar Life Sciences, Inc.; Nektar Therapeutics; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc. He is a consultant for Alexion Pharmaceuticals, Inc.; AstraZeneca/Medimmune; Biogen Idec; Boehringer-Ingelheim; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Eli Lilly and Company; EMD Serono, Inc.; Equillium, Inc.; Galapagos; Genentech, Inc./Roche; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Kezar Life Sciences, Inc.; MorphoSys US Inc.; Novartis; Reistone Biopharma; Sanofi; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc. He is an investigator for Amgen Inc.; AstraZeneca/Medimmune; Biogen Idec; Bristol-Myers Squibb Company; Boehringer-Ingelheim; Eli Lilly and Company; EMD Serono, Inc.; Equillium, Inc.; Genentech, Inc./Roche; GlaxoSmithKline; Kezar Life Sciences, Inc.; Nektar Therapeutics; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc. He is a committee member for the Lupus Research Alliance and The Lupus Academy.

Jeffrey Helfand, DO (peer reviewer) has no disclosures to report.

Mae Ochoa, RPh (peer reviewer) has no disclosures to report.

Susan Perry (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

CME Outfitters, LLC and the faculty do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


This document was last modified on:

PD-048-021121-13